SRNE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SRNE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Sorrento Therapeutics's change in working capital for the quarter that ended in Jun. 2023 was $33.45 Mil.
Sorrento Therapeutics's change in working capital for the fiscal year that ended in Dec. 2022 was $69.55 Mil.
It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).
The historical data trend for Sorrento Therapeutics's Change In Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sorrento Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Change In Working Capital | Get a 7-Day Free Trial | 6.14 | 7.45 | 3.80 | -2.79 | 69.55 |
Sorrento Therapeutics Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Change In Working Capital | Get a 7-Day Free Trial | 5.71 | 24.91 | 43.57 | 30.64 | 33.45 |
Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $132.56 Mil.
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.
Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.
Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC
Consolidated Statements of Cash Flows | Fiscal Years Ended | January 31, | (Amounts in millions) |
Cash flows from operating activities: | 2014 | 2013 | 2012 |
Changes in certain assets and liabilities, net of effects of acquisitions: | |||
Receivables, net | (566) | (614) | (796) |
Inventories | (1,667) | (2,759) | (3,727) |
Accounts payable | 531 | 1,061 | 2,687 |
Accrued liabilities | 103 | 271 | (935) |
Accrued income taxes | (1,224) | 981 | 994 |
For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Sorrento Therapeutics's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.
Henry Ji | director, officer: See Remarks | 5370 RUETTE DE MER, SAN DIEGO CA 92130 |
Tammy Reilly | director | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121 |
Kim Janda | director | 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121 |
Elizabeth Czerepak | director | 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070 |
Dorman Followwill | director | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121 |
Najjam Asghar | officer: Chief Financial Officer | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121 |
Robin L Smith | director | C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747 |
Edgar Lee | director | C/O OAKTREE CAPITAL MANAGEMENT, L.P., 333 SOUTH GRAND AVE, 28TH FLOOR, LOS ANGELES CA 90071 |
Jerome B Zeldis | officer: See Remarks | 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258 |
Jaisim Shah | director | C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560 |
Yue Alexander Wu | director | C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121 |
David Lemus | director | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121 |
Abg Management Ltd | 10 percent owner | UNIT 3002-04,30TH FLOOR,GLOUCESTER TOWER, THE LANDMARK,15 QUEEN'S ROAD CENTRAL, HONG KONG K3 000000 |
Jiong Shao | officer: Chief Financial Officer | SUITE 1003-1004, 10/F, ICBC TOWER, THREE GARDEN ROAD, CENTRAL, HONG KONG F4 000000 |
George K Ng | officer: See Remarks | C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121 |
From GuruFocus
By sperokesalga sperokesalga • 02-13-2023
By PRNewswire PRNewswire • 03-17-2023
By PRNewswire PRNewswire • 01-03-2023
By sperokesalga sperokesalga • 02-13-2023
By PRNewswire PRNewswire • 03-29-2023
By Stock market mentor Stock market mentor • 01-09-2023
By Marketwired • 06-26-2023
By GlobeNewswire GlobeNewswire • 02-19-2023
By GlobeNewswire GlobeNewswire • 02-05-2023
By GuruFocus Research • 02-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.